Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment.
COVID-19
cancer
nirmatrelvir/ritonavir
real-life data
remdesivir
vaccine
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
09
2022
accepted:
03
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26-80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73
Identifiants
pubmed: 36388947
doi: 10.3389/fmed.2022.1036473
pmc: PMC9643502
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1036473Informations de copyright
Copyright © 2022 Lasagna, Cassaniti, Lilleri, Quaccini, Ferrari, Sacchi, Bruno, Baldanti and Pedrazzoli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Therapie. 2022 Sep-Oct;77(5):509-521
pubmed: 35618549
Trop Med Infect Dis. 2022 May 22;7(5):
pubmed: 35622708
ESMO Open. 2022 Oct;7(5):100574
pubmed: 36029652
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Ther Drug Monit. 2022 Aug 09;:
pubmed: 35944126
J Inflamm Res. 2022 Aug 25;15:4907-4920
pubmed: 36046662
J Clin Med. 2022 Jul 01;11(13):
pubmed: 35807123
Emerg Infect Dis. 2022 Jun;28(6):1301-1302
pubmed: 35416767
JAMA. 2022 Jun 28;327(24):2380-2382
pubmed: 35675094